• last year
A new COVID-19 vaccine from Moderna is showing strong protection against a subvariant of the virus, providing reassurance to public health officials. The vaccine was originally designed for a dominant variant but has shown promising results against the subvariant. The subvariant is not yet prevalent enough to be listed on the CDC's variant tracker and does not cause more severe illness. Moderna, Pfizer, BioNTech, and Novavax are all planning updated vaccines. The CDC's Advisory Committee on Immunization Practices will meet on Tuesday to discuss approval for the updated vaccines.
Transcript
00:00 It's Benzinga and here's what's on the block.
00:02 - A new COVID-19 vaccine from Moderna
00:04 is showing strong protection against a sub-variant
00:07 of the virus, providing reassurance
00:09 to public health officials.
00:11 The vaccine was originally designed for a dominant variant
00:13 but has shown promising results against the sub-variant.
00:17 The sub-variant is not yet prevalent enough
00:19 to be listed on the CDC's variant tracker
00:21 and does not cause more severe illness.
00:24 Moderna, Pfizer, BioNTech and Novavax
00:27 are all planning updated vaccines.
00:30 The CDC's Advisory Committee on Immunization Practices
00:33 will meet on Tuesday to discuss approval
00:35 for the updated vaccines.
00:37 - For all things money, visit Benzinga.com.

Recommended